Good news! An MBA has been named the organization’s Chief Commercial Officer.

Good news! An MBA has been named the organization’s Chief Commercial Officer…

By purchasing Visant Medical, Inc. (Visant), a pioneer in medical technology innovation for Dry Eye Disease (DED), Nordic Pharma has broadened its pharmaceutical experience in the United States. Among them was the FDA-approved hyaluronic acid derivative LACRIFILL®, a canalicular occlusive device designed to obstruct the canalicular system and temporarily stop tear outflow.

“Dr Parekh’s 25 years of experience in eye care, strategic leadership, and deep understanding of eye care and the industry make him the perfect choice to guide our commercial entry into the U.S. market,” stated Charlotte Phelps, CEO of Nordic Pharma. “This acquisition is exciting, and we have big plans for LACRIFILL globally. “Dr. Parekh’s patient-driven focus as a practicing ophthalmologist will also be invaluable for making a lasting impact on the health of people with dry eye disease.”

The head of the American team launching LACRIFILL under the Nordic Pharma brand, Philip Gioia, said, “I’m excited to work with Jai in his new position. I’ve had the wonderful chance to collaborate with him at many top international ophthalmology firms. His expertise, knowledge, and reputation in our sector are unparalleled, and he offers a cutting edge, novel, and original approach to the field of eye care. Moreover, the appointment of Andy Corley from Yelroc Consulting as Nordic Pharma’s commercial adviser subsequent to the Visant Medical purchase positions us for success as we get ready to introduce LACRIFLL later this year.

Dr. Parekh expressed his gratitude at becoming a member of Nordic Pharma, a business renowned for its dedication to innovation and bettering patient outcomes. As we lead effective commercial initiatives, I look forward to assisting the organisation develop and succeed. There are several approaches to treating people with dry eyes, and given the enormous market potential, we think LACRIFILL will play a big role in the arsenal.

Together with Dr. Parekh, Nordic Pharma has appointed Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma) to its U.S. Medical Advisory Board. “I’m thrilled to have many of the top eye care leaders on our Medical Advisory Board,” Dr. Parekh went on. Together, we will contribute to providing cutting-edge care for the unmet needs of many ophthalmic patients.

This week at the Hawaiian Eye and Retina 2024 conference, Dr. Parekh and Andy Corley are representing Nordic Pharma in their new capacities. In addition to offering a limited number of pre-order chances, they will be discussing the advantages of LACRIFILL with ophthalmology experts and doctors at the conference.

Concerning Jai G. Parekh, M.D., MBA

Dr Parekh has long been involved in the field; he was best known for his work as the Chief Medical Officer of Allergan Eye Care. He is a frequent counsellor to several eye care organisations and serves on numerous advisory boards, associations, and foundations, including non-profits. As a practicing ophthalmologist, Dr Parekh is presently the CEO/Co-Founder of Eyecare Consultants of NJ. He was most recently appointed Chief Commercial Officer of Inizio Engage. He graduated from Boston University School of Medicine’s early admission medical programme with a doctorate. He is a board-certified ophthalmologist and dual-trained internist who completed his chief year and ophthalmology training at Boston University Medical Centre. He afterwards completed a fellowship in cornea/anterior segment/refractive surgery at the New York Eye & Ear Infirmary, where he is currently a clinical associate professor. Additionally, Dr. Parekh earned an MBA from Duke University’s Fuqua School of Business.

About Nordic Group B.V.

Nordic Group B.V. is a privately held, multinational pharmaceutical enterprise of moderate size, specialising in the creation and marketing of speciality pharmaceuticals. Build a foundation in Women’s Health, Rheumatology, and Eye Care with targeted innovations and selective acquisitions to improve the portfolio. Having planted strong roots throughout Europe, Nordic Pharma has lately boosted its global acquisitions to reach new markets.

Founded in 2019, SEVER Life Sciences is a holding company that includes Nordic Pharma. The three firms are complimentary and provide a broad variety of goods, pharmaceutical research services, and delivery systems.

Concerning Amring Pharmaceuticals, Inc.

Amring Pharmaceuticals Inc., a Nordic Group B.V. subsidiary, has partnerships with well-known international biopharmaceutical companies and is in a unique position to take advantage of its experience in introducing cutting-edge technologies, sterile manufacturing, and medications derived from biotechnology to the market.

Concerning Visant Medical, Inc.

Medical device business Visant Medical is in the clinical stage. The FDA granted approval for the LACRIFILL® cross-linked hyaluronic acid-based canalicular occlusive device in 2022 (510(k)). LACRIFILL aims to obstruct the canalicular system in order to prevent tear drainage. Patients exhibiting signs of dry eyes may take it for up to six months.

By using its knowledge of tissue regeneration, reconstruction, and associated delivery methods, Lyon, France-based Symatese SAS played a key role in the development of LACRIFILL, greatly improving the product’s design and functionality. SYMATESE is an expert in injectable crosslinked HA gels for a variety of applications, such as ophthalmology, rheumatology, and aesthetics. With over 40 researchers, SYMATESE creates the most cutting-edge medical device solutions with their range of silicone, thermoplastics, collagen, and hyaluronic acid technologies.

Secure Harbour

The business advances of Amring/Nordic Pharma and the execution of the company’s strategic ambitions are only two examples of the forward-looking statements included in this news release. These forward-looking statements include risks and uncertainties that might cause actual developments and results to vary considerably from Amring/Nordic Pharma’s expectations since they represent the company’s current views, assumptions, and beliefs about future events. Regulatory developments, general market circumstances, changes in the financial standing of third parties who interact with Amring/Nordic Pharma, and other variables that may have an impact on the company’s operations and financial results are just a few of the variables that fall under this category. Whether due to new information, unforeseen events, or other reasons, Amring/Nordic Pharma disclaims any duty to publicly update any forward-looking statements.